Bavarian Nordic rises on FDA approval for chikungunya vaccine

Bavarian Nordic A/S

17/02/2025 08:28

** Shares in Danish biotech Bavarian Nordic  BAVA.CO  rise
around 3% after it said on Friday it had received U.S. FDA
approval for its chikungunya vaccine for people aged 12 and
older 
    ** Bavarian aims to make Vimkunya commercially available in
the U.S. and launch it in key European markets in first half of
2025, it said in a statement
    ** The stock is on track for its best day since January 9 if
the gains hold

(Reporting by Elviira Luoma)
((Elviira.luoma@thomsonreuters.com))